经心室二尖瓣修复的中期结果:单中心经验
这项非随机观察性研究纳入88例因重度退行性二尖瓣反流行经心室二尖瓣修复的患者,按瓣膜病理位置分为A、B、C、D四型。中位随访42个月,33%出现大于2+的复发性二尖瓣反流,20.5%再次手术;A型装置成功率在6个月及以后为82%,C型1个月为53%、24个月降至20%。
要点
- 孤立P2脱垂经心室修复后3年装置成功率仅82%
- 复杂退行性病理(B、C型)反流进展与复发风险更高
- 左室扩大与C型病理是反流复发的独立危险因素
核心结论
- 经心室二尖瓣修复对孤立P2脱垂可初步减少反流,但3年耐久性仅82%,复杂退行性病理复发风险更高。
研究设计与样本
- 非随机观察性单中心研究,纳入2011至2017年88例因重度退行性二尖瓣反流行经心室二尖瓣修复的患者(平均年龄60岁,69%为男性),按病理位置分为A、B、C、D四型,采用Kaplan-Meier法、混合效应连续比例模型和多变量Cox回归分析。
主要发现
- 中位随访42个月(四分位距27-55),83例(94.3%)随访完整,晚期死亡3例(2例心源性、1例非心源性)。
- 29例(33%)出现大于2+的复发性二尖瓣反流,18例(20.5%)接受再次手术。
- A型装置成功率在6个月及以后为82%;B型在6、12、36个月分别为87%、85%、75%;C型1个月为53%、24个月为20%。
- 术前左室舒张末期内径更大、B型病理和C型病理者术后二尖瓣反流进展概率更高(P < .05)。
- 反流复发危险因素包括左室增大(风险比1.11;95%CI 1.04-1.20;P = .001)和C型病理(风险比5.99;95%CI 1.87-19.21;P = .003)。
关键数值与推荐
- 复发性二尖瓣反流大于2+见于29例(33%),再次手术18例(20.5%)。
- A型装置成功率6个月及以后82%;B型6、12、36个月分别为87%、85%、75%;C型1个月53%、24个月20%。
- 反流复发风险比:左室增大1.11(95%CI 1.04-1.20;P = .001),C型病理5.99(95%CI 1.87-19.21;P = .003)。
临床怎么用
- 术前应评估二尖瓣病理分型与左室大小,对B、C型复杂退行性病变及左室扩大者预期反流复发风险较高,需加强随访并权衡修复策略。
局限性
- 单中心非随机观察性研究,样本量88例,随访中位42个月,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The study objective was to evaluate the midterm outcomes of transventricular mitral valve repair and its association with the initial anatomy of the mitral valve. METHODS: This nonrandomized observational study included 88 patients (mean age, 60 years; 69% were men) who underwent transventricular mitral valve repair for severe degenerative mitral regurgitation between 2011 and 2017. Mitral valve function was assessed by echocardiography at 1 and 6 months and annually after the procedure. According to the location of mitral valve pathology, all patients were stratified into 4 anatomic types (A, B, C, and D). Results were assessed using Kaplan-Meier method, mixed-effects continuation ratio model, and multivariable Cox regression. RESULTS: Median follow-up of 42 months (interquartile range, 27-55) was complete for 83 patients (94.3%). There were 3 late deaths: 2 cardiac and 1 noncardiac. Recurrent mitral regurgitation greater than 2+ was observed in 29 patients (33%), and 18 patients (20.5%) underwent repeat surgery. Device success was 82% in type A at 6 months and thereafter; 87%, 85%, and 75% at 6, 12, and 36 months in type B, respectively; and 53% at 1 month and 20% at 24 months in type C. Probability of postoperative mitral regurgitation progression was higher in patients with greater preoperative left ventricular end-diastolic diameter, type B pathology, and type C pathology (P < .05). Risk factors of mitral regurgitation recurrence included increased left ventricle size (hazard ratio, 1.11; 95% confidence interval, 1.04-1.20; P = .001) and type C pathology (hazard ratio, 5.99; 95% confidence interval, 1.87-19.21; P = .003). CONCLUSIONS: Initial acceptable mitral regurgitation reduction after transventricular mitral valve repair of isolated P2 prolapse was possible but found durable in only 82% at 3 years. Higher risk of mitral regurgitation recurrence occurred with complex degenerative pathology.
引用
- Budra M, Janušauskas V, Drąsutienė A, et al. Midterm results of transventricular mitral valve repair: Single-center experience. J Thorac Cardiovasc Surg. 2021. PMID: 33612306. doi:10.1016/j.jtcvs.2020.12.142
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。